查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612161

肛门癌市场：按产品、癌症类型和最终用户 - 2025-2030 年全球预测

Anal Cancer Market by Offering (Drugs, Therapy), Cancer Type (Adenocarcinoma, Melanoma, Squamous Cell Carcinoma), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年肛门癌市场规模为10.6亿美元，预计2024年将达10.6亿美元，复合年增长率为6.38%，预计2030年将达15.4亿美元。

儘管肛门癌是一种相对罕见的疾病，但由于发病率的上升和癌症筛检意识的提高，它越来越受到人们的关注。该领域的研究和投资范围包括早期诊断方法、先进的治疗性介入和治疗后护理，突显了由于与最终诊断相关的严重健康后果和死亡率而需要的必要性。对市场格局的主要研究涉及医疗保健提供者、製药公司和研究机构，旨在改善诊断和治疗通讯协定，最终为包括患者和医疗保健提供者在内的最终用户塑造市场格局。市场成长受到分子诊断的进步、免疫疗法的日益采用以及政府促进癌症研究的支持措施等因素的显着影响。此外，生活方式的改变导致人类乳突病毒（HPV）等危险因子的盛行率增加，凸显了有针对性的筛检计画和预防策略的潜在机会。

主要市场统计
基准年[2023] 10亿美元
预计年份 [2024] 10.6亿美元
预测年份 [2030] 15.4亿美元
复合年增长率（%） 6.38%

最新的机会在于人工智慧和巨量资料分析的整合，以增强个人化医疗和早期检测方法。公司可以利用这些技术来开发创新的诊断工具和治疗方法，以填补当前市场产品的巨大空白。然而，先进治疗方法的高成本、某些人群的认知度低以及新兴治疗方法的潜在副作用等挑战阻碍了市场渗透。监管障碍和大规模临床试验的需求使产品的快速开发变得更加复杂。

创新成长可能来自对新治疗方法的研究，例如 CAR-T 细胞疗法和特异性针对 HPV 致癌病毒株的疫苗。此外，生物技术公司和学术机构之间的合作可以加速尖端解决方案的发展。为了挖掘市场潜力，公司正在投资教育宣传活动，以提高意识并促进早期筛检，与政策制定者合作简化核准流程，并减少获得治疗的财务障碍，重点应放在克服成本效益的解决方案上。肛门癌市场仍然充满活力，鑑于这种成长轨迹以及全球对综合癌症治疗的日益关注，具有重大创新的空间。

市场动态：揭示快速发展的肛门癌市场的关键市场洞察

供需的动态交互作用正在改变肛门癌市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界各地肛门癌的盛行率正在增加
    • 政府支持肛门癌治疗的投资和倡议
  • 市场限制因素
    • 用于治疗肛门癌的药物和治疗方法的昂贵
  • 市场机会
    • 核准治疗肛门癌的新药和治疗方法
    • 新药研发投资
  • 市场挑战
    • 肛门癌药物和治疗方法的长期影响

波特五力战略工具驾驭肛门癌市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肛门癌市场的外部影响

外部宏观环境因素在塑造肛门癌市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肛门癌市场的竞争状况

对肛门癌市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肛门癌市场供应商的绩效评估

FPNV定位矩阵是评估肛门癌市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了肛门癌市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对肛门癌市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地肛门癌的盛行率正在增加。
      • 政府对肛门癌治疗的支持性投资与倡议
    • 抑制因素
      • 用于治疗肛门癌的药物和治疗方法的昂贵
    • 机会
      • 核准治疗肛门癌的新药和治疗方法
      • 新药研发投资
    • 任务
      • 肛门癌药物和治疗方法的长期影响
  • 市场区隔分析
    • 我们提供什么：持续进步和监管支持，以改善肛门癌的治疗选择
    • 癌症类型：鳞状细胞癌的病例不断增加，增加了对快速有效的诊断和治疗性介入的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肛门癌市场：透过提供

  • 药品
    • Carboplatin
    • Cisplatin
    • Fluorouracil
    • 亚叶酸
    • Mitomycin
    • Oxaliplatin
  • 治疗
    • 化疗
    • 放射治疗
    • 标靶治疗

第七章依癌症类型分類的肛门癌市场

  • 腺癌
  • 恶性黑色素瘤
  • 鳞状细胞癌

第八章肛门癌市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第9章美洲肛门癌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太肛门癌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的肛门癌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA 核准纳武单抗联合治疗治疗进行性尿路上皮癌
    • FDA核准临时进口中国製造的Cisplatin以解决化疗短缺问题
    • Alembic PharmaFluorouracil注射液获得美国FDA核准
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • ADVANCED MARKER DISCOVERY, SL
  • Alembic Pharmaceuticals Limited
  • Alembic Pharmaceuticals Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • bioMerieux SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co. Ltd
  • Regeneron Pharmaceuticals Inc.
  • SANOFI WINTHROP INDUSTRIE
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CD5A9334D00D

The Anal Cancer Market was valued at USD 1.00 billion in 2023, expected to reach USD 1.06 billion in 2024, and is projected to grow at a CAGR of 6.38%, to USD 1.54 billion by 2030.

Anal cancer, though relatively rare, has been witnessing increased attention due to rising incidence rates and heightened awareness about cancer screenings. The scope of research and investment in this area encompasses early diagnosis methods, advanced therapeutic interventions, and post-treatment care, emphasizing the necessity due to the severe health implications and mortality rates associated with late-stage diagnoses. The primary applications of market insights in anal cancer involve healthcare providers, pharmaceutical companies, and research institutions aiming to refine diagnostics and treatment protocols, ultimately shaping the landscape for end-users including patients and healthcare providers. Market growth is notably influenced by factors such as advancements in molecular diagnostics, increasing adoption of immunotherapy, and supportive government initiatives promoting cancer research. Furthermore, lifestyle changes contributing to a higher prevalence of risk factors such as Human Papillomavirus (HPV) highlight potential opportunities for targeted screening programs and preventative strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.00 billion
Estimated Year [2024] USD 1.06 billion
Forecast Year [2030] USD 1.54 billion
CAGR (%) 6.38%

Latest opportunities lie in the integration of AI and big data analytics to enhance personalized medicine and early detection approaches. Companies can leverage these technologies to develop innovative diagnostic tools and treatments, filling notable gaps in current market offerings. Nonetheless, challenges such as the high costs of advanced treatments, limited awareness in certain populations, and potential side effects of emerging therapies hinder market penetration. Regulatory hurdles and the need for extensive clinical trials further complicate rapid product development.

Innovative growth could be driven by research into newer treatment modalities like CAR-T cell therapy and vaccines specifically targeting oncogenic strains of HPV. Additionally, partnerships between biotech firms and academic institutions could fast-track the development of cutting-edge solutions. To capitalize on market potential, businesses should invest in educational campaigns to increase awareness and promote early screening, collaborate with policymakers to streamline approval processes, and focus on cost-effective solutions to overcome financial barriers in treatment access. The anal cancer market remains dynamic, with room for substantial innovation given these growth trajectories and the increasing global focus on comprehensive cancer care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anal Cancer Market

The Anal Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of anal cancer across the globe
    • Supportive government investments and initiatives for anal cancer treatments
  • Market Restraints
    • Expensive nature of drugs and therapies used to treat anal cancer
  • Market Opportunities
    • Approvals for new drugs and therapies for anal cancer treatment
    • Investments in research and development of novel drugs
  • Market Challenges
    • Long-term consequences of anal cancer drugs and therapies

Porter's Five Forces: A Strategic Tool for Navigating the Anal Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anal Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anal Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anal Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anal Cancer Market

A detailed market share analysis in the Anal Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anal Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anal Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anal Cancer Market

A strategic analysis of the Anal Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anal Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADVANCED MARKER DISCOVERY, S.L., Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, bioMerieux SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Ipsen Pharma, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Qilu Pharmaceutical Co. Ltd, Regeneron Pharmaceuticals Inc., SANOFI WINTHROP INDUSTRIE, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Drugs and Therapy. The Drugs is further studied across Carboplatin, Cisplatin, Fluorouracil, Leucovorin, Mitomycin, and Oxaliplatin. The Therapy is further studied across Chemotherapy, Radiation Therapy, and Targeted Therapy.
  • Based on Cancer Type, market is studied across Adenocarcinoma, Melanoma, and Squamous Cell Carcinoma.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of anal cancer across the globe
      • 5.1.1.2. Supportive government investments and initiatives for anal cancer treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of drugs and therapies used to treat anal cancer
    • 5.1.3. Opportunities
      • 5.1.3.1. Approvals for new drugs and therapies for anal cancer treatment
      • 5.1.3.2. Investments in research and development of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Long-term consequences of anal cancer drugs and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Ongoing advancements and regulatory support to improve the therapy options for anal cancer
    • 5.2.2. Cancer Type: Rising cases of squamous cell carcinomas and need for quick and effective diagnostics and treatment interventions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anal Cancer Market, by Offering

  • 6.1. Introduction
  • 6.2. Drugs
    • 6.2.1. Carboplatin
    • 6.2.2. Cisplatin
    • 6.2.3. Fluorouracil
    • 6.2.4. Leucovorin
    • 6.2.5. Mitomycin
    • 6.2.6. Oxaliplatin
  • 6.3. Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Radiation Therapy
    • 6.3.3. Targeted Therapy

7. Anal Cancer Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Adenocarcinoma
  • 7.3. Melanoma
  • 7.4. Squamous Cell Carcinoma

8. Anal Cancer Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Anal Cancer Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anal Cancer Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anal Cancer Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Sanctions Nivolumab Combo for Advanced Urothelial Carcinoma
    • 12.3.2. FDA Approves Temporary Import of Chinese-Made Cisplatin to Address Chemotherapy Shortage
    • 12.3.3. Alembic Pharma Secures USFDA Approval for Fluorouracil Injection
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. ADVANCED MARKER DISCOVERY, S.L.
  • 3. Alembic Pharmaceuticals Limited
  • 4. Alembic Pharmaceuticals Ltd
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. bioMerieux SA
  • 10. Boehringer Ingelheim GmbH
  • 11. Bristol-Myers Squibb Company
  • 12. DAIICHI SANKYO COMPANY, LIMITED.
  • 13. Eli Lilly and Company
  • 14. F. Hoffmann-La Roche Ltd
  • 15. GlaxoSmithKline plc.
  • 16. Ipsen Pharma
  • 17. Johnson & Johnson Services, Inc.
  • 18. Merck KGaA
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Qilu Pharmaceutical Co. Ltd
  • 22. Regeneron Pharmaceuticals Inc.
  • 23. SANOFI WINTHROP INDUSTRIE
  • 24. Taj Pharmaceuticals Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANAL CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ANAL CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANAL CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANAL CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANAL CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANAL CANCER MARKET SIZE, BY FLUOROURACIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANAL CANCER MARKET SIZE, BY LEUCOVORIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANAL CANCER MARKET SIZE, BY MITOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANAL CANCER MARKET SIZE, BY OXALIPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANAL CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023